Top 20 Companies in Global Cimzia (certolizumab) Drug Market (2025–2035): Competitive Analysis & Forecast

Description

According to a research report published by Spherical Insights & Consulting, the Global Cimzia (certolizumab) drug Market Size is projected to grow from USD 3.26 Billion in 2024 to USD 8.1 Billion by 2035, at a CAGR of 8.63% during the forecast period 2025–2035. The Global Cimzia (certolizumab) drug Market is driven by the increasing prevalence of autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and Crohn's disease, which is expected to increase the demand for effective treatment options such as Cimzia (certolizumab).

 

Introduction

The global market for Cimzia (certolizumab pegol) remains a critical segment of the biologics landscape, particularly within the tumor necrosis factor (TNF) inhibitor class. Cimzia is defined as a PEGylated, Fc-free antigen-binding fragment (Fab') of a humanized monoclonal antibody designed to neutralize TNF-alpha, a primary driver of inflammation. Its unique molecular structure differentiates it from other anti-TNF agents like adalimumab or infliximab; by lacking an Fc region, it exhibits minimal placental transfer, making it a pivotal therapeutic option for pregnant and breastfeeding women with chronic inflammatory conditions. Innovation in this market is characterized by advanced delivery systems and chemical modifications aimed at improving patient adherence and clinical outcomes. The conjugation of the Fab fragment to polyethylene glycol (PEG) significantly extends the drug's half-life and enhances its selectivity for inflamed tissues. Furthermore, the development of connectivity-enabled sensors for injection devices represents a burgeoning trend to support real-time patient management and data tracking. The market is primarily driven by the rising prevalence of autoimmune disorders such as rheumatoid arthritis, plaque psoriasis, and Crohn’s disease. While the broader biologics market is experiencing a significant shift toward biosimilars due to patent expirations, including Cimzia's own patent loss in 2021, the absence of immediate biosimilar entrants in certain regions like Canada has helped maintain its original market position.

 

Navigate Future Markets with Confidence: Insights from Spherical Insights LLP

The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Cimzia (certolizumab) Drug Market.

 

Cimzia (certolizumab) drug Market Size & Statistics

• The Market Size for Cimzia (certolizumab) drug Was Estimated to be worth USD 3.26 Billion in 2024.
• The Market is Going to Expand at a CAGR of 8.63% between 2025 and 2035.
• The Global Cimzia (certolizumab) drug Market Size is anticipated to reach USD 8.1 Billion by 2035.
• North America is expected to generate the highest demand during the forecast period in the Cimzia (certolizumab) drug Market
• Asia Pacific is expected to grow the fastest during the forecast period in the Cimzia (certolizumab) drug Market.

Regional growth and demand

  Asia Pacific is expected to grow the fastest during the forecast period in the Cimzia (certolizumab) drug market. Asia Pacific is expected to grow fastest due to massive government investments in healthcare modernization and an increasing geriatric population susceptible to inflammatory disorders. Additionally, rising disposable incomes and the gradual introduction of cost-effective generic alternatives are enhancing the accessibility of advanced biologic treatments across emerging economies such as  China and India.

 

North America is expected to generate the highest demand during the forecast period in the Cimzia (certolizumab) drug market. North America is expected to generate the highest demand due to a sophisticated healthcare infrastructure, high patient awareness of biologic therapies, and favorable reimbursement frameworks that facilitate access to high-cost specialty drugs. Furthermore, the region’s leadership is reinforced by the presence of major pharmaceutical research hubs and a significant prevalence of autoimmune conditions like rheumatoid arthritis and Crohn’s disease.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Cimzia (certolizumab) Drug Market.

 

Top 10 Trends in the Cimzia (certolizumab) Drug Market

• Expansion into Non-Radiographic Indications
• Dominance in Maternal Health Protocols
• Rise of Self-Administration Solutions
• Integration of Digital Health Tools
• Increased Focus on Real-World Evidence (RWE)
• Sustainability in Manufacturing
• Expanded Use in Dermatology
• Telehealth Integration for Monitoring
• Precision Medicine and Biomarker Research
• Focus on Patient-Centric Design

 

1. Dominance in Maternal Health Protocols

A unique trend for Cimzia is its status as a preferred TNF inhibitor for pregnant and breastfeeding women. Due to its Fc-free molecular structure, there is minimal placental transfer. Clinical guidelines are increasingly reflecting this safety profile, making it the "gold standard" biologic for women of childbearing age with autoimmune disorders.

 

1. Rise of Self-Administration Solutions

There is a significant shift toward home-based care, with patients preferring self-injection over clinic visits. Trends show high demand for prefilled syringes and auto-injector pens (like the Ava® device), which are designed for ease of use by patients with limited manual dexterity, such as those suffering from severe rheumatoid arthritis.

 

1. Integration of Digital Health tools

The market is incorporating "smart" injection devices and mobile health apps to track patient adherence. These tools allow patients to record injection sites and dates, while providing physicians with real-world data on treatment consistency, which is crucial for managing chronic inflammatory diseases.

 

1. Focus on Patient-Centric Design

UCB (the manufacturer) has led a trend in "inclusive design" for packaging. Cimzia’s packaging often features easy-to-grip surfaces and large-print instructions, specifically catering to the elderly and those with joint degeneration, which improves patient satisfaction and brand loyalty.

 

1. Telehealth Integration for Monitoring

UCB (the manufacturer) has led a trend in inclusive design for packaging. Cimzia’s packaging often features easy-to-grip surfaces and large-print instructions, specifically catering to the elderly and those with joint degeneration, which improves patient satisfaction and brand loyalty.

 

Empower your strategic planning:

Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the cimzia (certolizumab) drug market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Cimzia (certolizumab) Drug Market.

 

Top 20 Companies Leading the Cimzia (certolizumab) drug Market

1. UCB S.A.
2. Ferring Pharmaceuticals
3. Dermira
4. Astellas Pharma
5. Advanz Pharma
6. Zentiva Group
7. Stada Arzneimittel
8. Biogen
9. Xbrane Biopharma
10. Alvotech
11. Lupin Limited
12. Samsung Bioepis
13. Paras Biopharmaceuticals
14. Celltrion Healthcare
15. Mycenax Biotech
16. AbbVie
17. Pfizer
18. MSD
19. Bristol-Myers-Squibb
20. Amgen

 

1. UCB.S. A

Headquarters: Brussels, Belgium

UCB, active in over 40 countries, is the originator and patent holder of Cimzia, UCB S.A. is the central pillar of this market. The company is a global biopharmaceutical leader with a heavy focus on neurology and immunology. UCB’s primary activity involves the continuous research, development, and global commercialization of certolizumab pegol. Their contribution to the market is defined by their patient-value strategy, which led to the unique molecular engineering of Cimzia. By removing the Fc region of the antibody, UCB successfully positioned the drug as a specialized solution for pregnant women and patients with specific inflammatory needs. They manage the entire lifecycle of the product, from initial clinical trials for new indications like non-radiographic axial spondyloarthritis to the design of ergonomic injection devices.

 

1. Astellas Pharma

Headquarters: Tokyo, Japan

Astellas Pharma, active in over 70 countries, plays a vital role in the Cimzia market through its deep-rooted commercialization expertise in the Asian landscape. While UCB developed the drug, Astellas serves as the primary distribution and promotion partner in Japan, a key geographic segment. Their activity is focused on navigating the complex regulatory environment of the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to ensure Cimzia remains a top-tier choice for rheumatoid arthritis patients. Astellas leverages its massive sales force and established relationships with hospitals to maintain the drug’s market presence against local competitors.

 

1. Biogen

Headquarters: Cambridge, Massachusetts, USA

Biogen, active in over 40 countries, is a titan in the biotechnology sector, traditionally known for its work in multiple sclerosis, but it has recently become a major force in the Cimzia biosimilar market. Their activity is primarily driven through a high-stakes commercialization agreement with Xbrane Biopharma. Biogen’s role is to take the lead on the global launch and marketing of Xcimzane, a biosimilar candidate for certolizumab pegol. This involves managing the late-stage regulatory filings and preparing the market for a lower-cost alternative to the originator drug. Biogen brings a sophisticated infrastructure for biologics to the table, allowing them to compete with other TNF-inhibitors.

 

1. Xbrane Biopharma

Headquarters: Stockholm, Sweden

Xbrane Biopharma, active in approximately 15 countries through development partnerships, is a specialized biotechnology firm that focuses on the complex development of biosimilars using unique high-yield expression platforms. In the Cimzia market, Xbrane is the scientific engine behind one of the most prominent biosimilar candidates. Their activity is centered on the technical replication of certolizumab pegol, ensuring that the biosimilar matches the originator’s efficacy and safety profiles. Unlike larger commercial firms, Xbrane’s expertise lies in the lab-to-pilot phase, where they optimize the production of the PEGylated Fab' fragment.

 

1. Alvotech

Headquarters: Reykjavik, Iceland

Alvotech, active in over 30 countries, is a pure-play biosimilar company that has built a state-of-the-art facility dedicated entirely to the development and manufacture of biologic medicines. Their activity in the Cimzia market revolves around their candidate, AVT10, a biosimilar to certolizumab pegol. Alvotech’s strategy is unique because they focus on vertical integration they handle everything from cell line development to final commercial manufacturing in their high-tech Icelandic hub. In the context of the global market, Alvotech acts as a supply-chain stabilizer, aiming to provide a high-volume, consistent alternative to Cimzia. They have formed a complex web of alliances with other pharmaceutical firms to handle local distribution, allowing Alvotech to focus on the intricate chemistry required to produce a stable, PEGylated antibody fragment.

 

Are you ready to discover more about the cimzia (certolizumab) drug market?

The report provides an in-depth analysis of the leading companies operating in the global cimzia (certolizumab) drug market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Cimzia (certolizumab) Drug Market.

 

Company Profiles

1. UCB S.A

• Business Overview
• Company Snapshot
• Products Overview
• Company Market Share Analysis
• Company Coverage Portfolio
• Financial Analysis
• Recent Developments
• Merger and Acquisitions
• SWOT Analysis

1. Astellas Pharma
2. Advanz Pharma
3. Zentiva Group
4. Stada Arzneimittel
5. Biogen
6. Xbrane Biopharma
7. Alvotech
8. Samsung Bioepis
9. Others.

 

Conclusion

The global Cimzia (certolizumab pegol) market is experiencing a transformative phase, characterized by sustained demand for specialized biologic therapies and the emergence of strategic biosimilar competition. Market expansion is primarily fueled by the rising incidence of chronic autoimmune conditions and Cimzia’s unique clinical niche as a preferred TNF-inhibitor for pregnant and breastfeeding women due to its Fc-free structure. Technological innovations, such as advanced PEGylation for extended half-life and ergonomic self-injection devices, continue to improve patient adherence and therapeutic outcomes. Key industry leaders, including UCB S.A., Biogen, Xbrane Biopharma, Alvotech, and Astellas Pharma, are actively shaping the landscape through R&D investment and global commercialization efforts. As the market transitions toward a more competitive environment with the introduction of cost-effective alternatives, Cimzia remains a cornerstone of precision immunology. Its role in providing tailored treatment options for complex inflammatory diseases ensures its continued relevance in the global pharmaceutical sector.

 

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.  Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter